Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure

Bioconjugate Chemistry

Volumn 15, Issue 6, 2004, Pages 1264-1274

  Safavy, Ahmad ^a,c,d   Georg, Gunda I ^e   Vander Velde, David ^e   Raisch, Kevin P ^a,d   Safavy, Kamellia ^b   Carpenter, Mark ^f   Wang, Wenquan ^c,d   Bonner, James A ^a,d   Khazaeli, M B ^a,d   Buchsbaum, Donald J ^a,d  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF KANSAS   (United States)

^f AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DRUG PRODUCTS; MAMMALS; TARGETED DRUG DELIVERY; TUMORS;

ANTIBODY CONJUGATE; ANTITUMOUR ACTIVITY; BIODISTRIBUTIONS; DRUG RELEASE; HALF LIVES; HUMAN PROSTATE; IN-VIVO; OH -; PACLITAXEL; TUMOR UPTAKE;

MONOCLONAL ANTIBODIES;

3' (4 HYDROXYPHENYL)PACLITAXEL; 3' (4 HYDROXYPHENYL)PACLITAXEL CETUXIMAB CONJUGATE I 125; ANTIBODY CONJUGATE; CETUXIMAB; DRUG METABOLITE; IODINE 125; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BIODIVERSITY; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PROSTATE CARCINOMA; TUMOR LOCALIZATION; XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 9244249218     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc049868v     Document Type: Conference Paper

References (34)

1. Pietersz, G. A., and McKenzie, I. (2002) The use of drug-monclonal antibody conjugates for the treatment of cancer, in Tumor Targeting in Cancer Therapy (Pagé, M, Ed.) pp 179-196. Humana Press, Totowa, NJ.
2. 188Rhenium-Labeled Trisuccin-ΔCH2HuCC49 as a Radioimmunotherapy Model in Nude Mice, in Drug Targeting in Cancer Therapy (Pagé, M, Ed.) pp 257-275, The Human Press Inc., Totowa, NJ.
3. Illidge, T. M., and Brock, S. (2000). Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr. Pharm. Des. 6, 1399-1418.
4. Kousparou, C. A., Deonarain, M. P., and Epenetos, A. A. (2000). Advances in tumour targeting. J. Int. Soc. Tumor Target. 1, 55-69.
5. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784.
6. Griffiths, G. L., Mattes, M. J., Stein, R., Govindan, S. V., Horak, I. D., Hansen, H. J., and Goldenberg, D. M. (2003). Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate. Clin. Cancer Res. 9, 6567-6571.
7. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002). An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem. 13, 40-46.
8. Stan, A. C., Radu, D. L., Casares, S., Bona, C. A., and Brumeanu, T. D. (1999). Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res. 59, 115-121.
9. Jekunen, A., Kairemo, K., and Karnani, P. (1996). In vivo modulators of antibody kinetics. Acta Oncol. 35, 267-271.
10. 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J. Nucl. Med. 44, 1148-1155.
11. Lee, F. T., Rigopoulos, A., Hall, C., Clarke, K., Cody, S. H., Smyth, F. E., Liu, Z., Brechbiel, M. W., Hanai, N., Nice, E. C., Catimel, B., Burgess, A. W., Welt, S., Ritter, G., Old, L. J., and Scott, A. M. (2001). Specific localization, gamma camera imaging, and intracellular trafficking of radiolabeled chimeric anti-G(DS) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res. 61, 4474-4482.
12. Reist, C. J., Archer, G. E., Wikstrand, C. J., Bigner, D. D., and Zalutsky, M. R. (1997). Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 57, 1510-1515.
13. Florent, J. C., Dong, X., Gaudel, G., Mitaku, S., Monneret, C., Gesson, J. P., Jacquesy, J. C., Mondon, M., Renoux, B., Andrianomenjanahary, S., Michel, S., Koch, M., Tillequin, F., Gerken, M., Czech, J., Straub, R., and Bosslet, K. (1998). Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 41, 3572-3581.
14. Wrasidlo, W., Gaedicke, G., Guy, R. K., Renaud, J., Pitsinos, E., Nicolaou, K. C., Reisfeld, R. A., and Lode, H. N. (2002). A novel 2′-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjugate Chem. 13, 1093-1099.
15. Wong, B. K., DeFeo-Jones, D., Jones, R. E., Garsky, V. M., Feng, D. M., Oliff, A., Chiba, M., Ellis, J. D., and Lin, J. H. (2001). PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab. Dispos. 29, 313-318.
16. DeFeo-Jones, D., Garsky, V. M., Wong, B. K., Feng, D. M., Bolyar, T., Haskell, K., Kiefer, D. M., Leander, K., McAvoy, E., Lumma, P., Wai, J., Senderak, E. T., Motzel, S. L., Keenan, K., Van Zwieten, M., Lin, J. H., Freidinger, R., Huff, J., Oliff, A., and Jones, R. E. (2000). A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 6, 1248-1252.
17. Safavy, A. Taxane derivatives for targeted therapy of cancer. US Patent 6,191,290, 2001.
18. Safavy, A., Raisch, K. P., Khazaeli, M. B., Buchsbaum, D. J., and Bonner, J. A. (1999). Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J. Med. Chem. 42, 4919-4924.
19. Safavy, A., Bonner, J. A., Waksal, H., Buchsbaum, D. J., Gillespie, G. Y., Khazaeli, M. B., Arani, R. B., Chen, D. T., Carpenter, M., and Raisch, K. P. (2003). Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjugate Chem. 14, 302-310.
20. Salacinski, P. R., McLean, C., Sykes, J. E., Clement-Jones, V. V., and Lowry, P. J. (1981). Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3alpha, 6alpha- diphenylglycoluril. Anal. Biochem. 117, 136-146.
21. Fraker, P. J., and Speck, J. C. (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4, 6-tetrachloro- 3α, 6α-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849-857.
22. Deutsch, H., Glinski, J., Hernandez, M., Haugwitz, R., Narayanan, V., Suffness, M., and Zalkow, L. (1989). Synthesis of congeners and prodrugs: Water soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32, 788-792.
23. Bhargava, K. K., and Acharya, S. A. (1989). Labeling of monoclonal antibodies with radionuclides. Semin. Nucl. Med. 19, 187-201.
24. Auzenne, E., Donate, N. J., Li, C., Leroux, E., Price, R. E., Farquhar, D., and Klostergaard, J. (2002). Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 8, 573-581.
25. Luo, Y., and Prestwich, G. D. (1999). Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem. 10, 755-763.
26. Sharma, A., Mayhew, E., Bolcsak, L., Cavanaugh, C., Harmon, P., Janoff, A., and Bernacki, R. J. (1997). Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 71, 103-107.
27. Sparreboom, A., Huizing, M. T., Boesen, J. J., Nooijen, W. J., van Tellingen, O., and Beijnen, J. H. (1995). Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother. Pharmacol. 36, 299-304.
28. Krishna Reddy, S. H., Lee, S., Datta, A., and Georg, G. I. (2001). Efficient synthesis of the 3′-phenolic metabolite of paclitaxel. J. Org. Chem. 66, 8211-8214.
29. Press, O. W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M. R., Hamann, P., Hinman, L., Shochat, D., and Bernstein, I. D. (1996). Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56, 2123-2129.
30. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. (1992). Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 52, 2907-2915.
31. Li, C., Yu, D., Inoue, T., Yang, D. J., Milas, L., Hunter, N. R., Kim, E. E., and Wallace, S. (1996). Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 7, 642-648.
32. Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., and Martinez, A. (1996). Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39, 424-431.
33. Mandolini, L. (1978). Ring-closure reactions. The activation parameters for the formation of four to six-membered lactones from w-Bromoalkanoate ions. The role of the entropy factor in small- and common-ring formation. J. Am. Chem. Soc. 100, 550.
34. Guillemard, V., and Saragovi, H. U. (2001). Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 61, 694-699.